



Neuren Pharmaceuticals Ltd
Level 1, 103 Carlton Gore Road
Newmarket, Auckland, New Zealand
office: +64 9 529 3940
fax: +64 9 529 3941
enquiries@neurenpharma.com
www.neurenpharma.com

5 February 2008

The Company Announcements Office
ASX Limited

BY E-LODGEMENT

For Release to the Market

Notice under section 708A(5)(e) of the Corporations Act

On 31 January 2008 the Company announced the results of the partially underwritten rights issue pursuant to the Investment Statement & Prospectus and Letter of Offer, both dated 19 December 2007. Allotment of the 40,677,213 shares was completed on 1 February 2008.

The Company relies on case 1 in section 708A(5) of the Corporations Act 2001 (Act) in respect of the issue of these rights issue shares.

The Company gives notice under paragraph (5)(e) of section 708A of the Act that:

1. The Company issued the rights issue shares without disclosure to the investors under Part 6D.2 of the Act;
2. As at the date of this notice the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act (as applicable to the Company); and
 - (b) section 674 of the Act; and
3. As at the date of this notice there is no excluded information (as defined in section 708A(7) of the Act) which is required to be disclosed by the Company.

Yours sincerely

A handwritten signature in black ink, appearing to read "Rob Turnbull".

Mr Rob Turnbull
Chief Financial Officer